Allogene Therapeutics disclosed an early look at Phase 2 consolidation data for its off-the-shelf CAR-T, cema-cel, in first-line large B-cell lymphoma (LBCL), reporting deeper minimal residual disease (MRD) clearance than the observation arm. In the futility analysis, 7 of 12 patients achieved MRD negativity versus 2 of 12 in the control group. Allogene framed the results as an important proof point for donor-derived CAR-T as a more convenient alternative to autologous approaches. The company said it is continuing enrollment in the broader study and expects later readouts in 2027. The early MRD signal also renews debate about how quickly investors will re-rate allogeneic cell-therapy platforms versus personalized CAR-T, based on durability and safety across larger cohorts.